Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 20-65 years;~2. Hypertension with average 24-hour BP of \>130 mmHg systolic or \>80 mmHg diastolic in spite of treatment with one medication;~3. Office systolic blood pressure \>140 mmHg and less than 180mmHg;~4. Able to comprehend and sign the consent form;~5. Able to tolerate either hydrochlorothiazide 25 mg or amlodipine 5 mg daily for 3 weeks during the run-in phase.~Exclusion Criteria:~1. Diagnosis of secondary hypertension;~2. Hypertension with systolic BP \>180 mmHg in spite of 1 medication;~3. Chronic heart failure requiring diuretics, Angina or coronary syndrome requiring anti-angina therapy with CCB or beta blockers, or more than 0.4 mg/hr nitroglycerine patch;~4. Left Ventricular Ejection Fraction (LVEF) \<20% or LV end systolic dimension \>75 mm;~5. Significant valvular disease such as; more than mild disease of aortic or mitral valve;~6. Technically sub-optimal acoustic window or regional wall motion abnormalities;~7. Patients currently on both CCB and diuretics for more than 4 weeks;~8. Normal 24 hour ABPM at the end of the run-in period;~9. Physical handicap that precludes adequate performance of 6-minute walk such as arthritis;~10. Concomitant comorbidity that might compromise ability to evaluate treatment or enhance risks of therapy, such as: atrial fibrillation with resting ventricular rate of \>100 bpm; morbid obesity; uncontrolled diabetes mellitus; severe chronic obstructive pulmonary disease (COPD); hypertrophic cardiomyopathy; and documented history of non-compliance with treatment;~11. Any condition or disorder other than hypertension that: Requires prolonged hospitalization; May limit life expectancy within 2 years; would increase the risk of participation to the subject (in the opinion of the investigator).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Diuretic-Based Hypertension Therapy
- 2 (Type: ACTIVE_COMPARATOR): Non-Diuretic-Based Hypertension Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).